Field experiments and wild population monitoring have been performed to study the population biology of the rare long-lived Kosteletzkya pentacarpos (Malvaceae) in the Llobregat delta (Catalonia, NE ...Spain). Field experiments explored the fate of seeds in soil at different depths, seedling emergence, and seedling survival, growth and flowering with and without canopy cover during the first 2 years of life. They also were used to ascertain the size-related pattern of seedling survivorship and flowering. Field data concerning mortality, growth and fecundity of adult plants were collected yearly in three wild populations for 7-9 years. In old adults (reproducing long before the beginning of the study), ANOVAR tests were performed to compare maximum diameter, total and fertile shoots, and viable seeds per plant between years and populations. New adults (starting flowering the first year of study or in subsequent years) were used to explore, using linear and polynomial regressions, the association of RGR and both total and fertile shoot production with (i) plant size (maximum basal diameter or its logarithm); (ii) plant age (years in adult stage); and (iii) plant age after removing the effect of size and year-to-year fluctuations. In this case, we examined the agerelated pattern of the residuals obtained from the regressions with size and year. The study identified the following main demographic features of K. pentacarpos: (i) transient, shallow soil seed bank; (ii) shade tolerance of seedling emergence; (iii) canopy-facilitation of seedling survival and bolting during the first two years of life; (iv) sizerelated pattern for seedling survivorship but not flowering; (v) exclusive dependence on a fluctuating seed output for reproduction; (vi) rapid adult growth; and (vii) high adult longevity but (viii) rapid depletion of fecundity with age. Seed output was highly constrained by mining insects. The changing size-structure and the decreasing reproductive success of old adults in several populations suggest that K. pentacarpos might undergo a dynamics of population establishment and extinction in the Ricarda marshes. Because of fluctuating reproduction and the lack of a persistent seed bank, the conservation of standing adult populations appears to be a key factor to ensure the persistence of the species.
Rare plant species have extremely narrow distributions that can be reduced to a single or few populations. The rare long-lived plant Kosteletzkya pentacarpos is one such species because only two ...extant localities are known in the western Mediterranean. In this study, we analyse the population dynamics over nine years of the only population known in north-east Spain, which is located at the Llobregat delta (Barcelona). We collected basic demographic data to build a transition matrix model. We computed population growth rates λ and their confidence intervals for each year of study. We conducted elasticity and variance decomposition analyses to determine the relative importance of vital rates to overall population dynamics. On average, the K. pentacarpos population exhibited an increasing dynamics. Survivorship of adult plants contributed the most to each λ, whereas temporal variance in fecundity and juvenile fate explained the observed variation in λ. Despite the increasing dynamics of K. pentacarpos, important reductions in fecundity resulting from biotic agents and recruitment owing to habitat limitations are constraints for population growth. We conclude that the knowledge generated in this long-term study should be used to create new K. pentacarpos populations at the Llobregat delta in order to minimize the risk of extinction following catastrophic events that are nearly impossible to predict.
Notas Breves Maria del Carmen López Rodríguez; Ignacio Bárbara Criado; Javier Cremades Ugarte ...
Anales del Jardín Botánico de Madrid (1979),
06/2002, Volume:
60, Issue:
1
Journal Article
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (
) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to
-T790M mutation (T790M). ...We sought to describe T790M changes in serum/plasma during osimertinib therapy and correlate these changes with treatment outcomes.
Serum/plasma from
-mutant lung cancer patients with T790M-AR was collected before and during osimertinib treatment. Changes in T790M were evaluated using a peptide-nucleic acid-PCR assay, and correlated with clinical and radiographic response.
Thirteen patients were included. Median time on osimertinib treatment was 10.6 months with a median progression-free survival of 13.6 months. Best response to osimertinib was partial response (PR), stable disease (SD) or progression (PD) in 46.1%, 30.8% and 23.1% of patients, respectively.Most of the patients were paucisymptomatic at baseline. Symptom improvement was reported in 66.6% of responder patients; while symptoms remained stable in 75% of patients with SD, and 66% of patients with PD had clinical deterioration.Three patterns of T790M changes during osimertinib treatment were identified. T790 remained detectable with PD or a short-lasting SD in 15.4% of the patients. T790M disappeared in 69.2% of patients with PR or SD. T790M disappeared, despite clinical and/or radiographic progression in 15.4% of the patients.
Changes of T790M in serum/plasma in
-mutant lung cancer patients with T790M-AR might be a useful marker of symptomatic and radiographic outcome to osimertinib. Longer follow-up is needed to establish if subsequent emergence of T790M could be a marker of resistance.
Background: The clinical relevance of recurrent venous thromboembolism (VTE) after discontinuing anticoagulation in patients with COVID-19-associated VTE remains uncertain. We estimated the incidence ...rates and mortality of VTE recurrences developing after discontinuing anticoagulation in patients with COVID-19-associated VTE. Methods: A prospective, multicenter, non-interventional study was conducted between March 25, 2020, and July 26, 2023, including patients who had discontinued anticoagulation after at least 3 months of therapy. All patients from the registry were analyzed during the study period to verify inclusion criteria. Patients with superficial vein thrombosis, those who did not receive at least 3 months of anticoagulant therapy, and those who were followed for less than 15 days after discontinuing anticoagulation were excluded. Outcomes were: 1) Incidence rates of symptomatic VTE recurrences, and 2) fatal PE. The rate of VTE recurrences was defined as the number of patients with recurrent VTE divided by the patient-years at risk of recurrent VTE during the period when anticoagulation was discontinued. Findings: Among 1106 patients with COVID-19-associated VTE (age 62.3 ± 14.4 years; 62.9% male) followed-up for 12.5 months (p25-75, 6.3–20.1) after discontinuing anticoagulation, there were 38 VTE recurrences (3.5%, 95% confidence interval CI: 2.5–4.7%), with a rate of 3.1 per 100 patient-years (95% CI: 2.2–4.2). No patient died of recurrent PE (0%, 95% CI: 0–7.6%). Subgroup analyses showed that patients with diagnosis in 2021–2022 (vs. 2020) (Hazard ratio HR 2.86; 95% CI 1.45–5.68) or those with isolated deep vein thrombosis (vs. pulmonary embolism) (HR 2.31; 95% CI 1.19–4.49) had significantly higher rates of VTE recurrences. Interpretation: In patients with COVID-19-associated VTE who discontinued anticoagulation after at least 3 months of treatment, the incidence rate of recurrent VTE and the case-fatality rate was low. Therefore, it conceivable that long-term anticoagulation may not be required for many patients with COVID-19-associated VTE, although further research is needed to confirm these findings. Funding: Sanofi and Rovi, Sanofi Spain.
PDF
